[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"refractory-indolent-b-cell-non-hodgkin-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:refractory-indolent-b-cell-non-hodgkin-lymphoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100545777","phase-2-reduced-dose-radiotherapy-for-the-treatment-of-indolent-non-hodgkin-lymphoma-100545777",false,"NCT06386315","Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma","MC230808 Reduced Dose Hypofractionated Radiotherapy (3Gy x 3 Fractions) for Indolent Non-Hodgkin Lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histological confirmation of indolent B-cell lymphoma that can include any of the following:\n\n  * Follicular lymphoma (grade 1 or 2 or 3A)\n  * Marginal zone lymphoma (nodal or extranodal)\n  * Follicle center lymphoma\n* Any stage disease\n* Initial, refractory, or relapsed disease. If relapse involves the site to be treated there must be evidence of disease progression\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 3\n* Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only\n* Provide written informed consent\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Willing to return to enrolling institution for follow-up visits (during the active monitoring phase of the study). Virtual visits can also be considered as an option for applicable items\n* Confirmation from radiation oncologist of suitability to participate in study\n\nExclusion Criteria:\n\n* Any of the following:\n\n  * Pregnant women\n  * Nursing women\n  * Women of childbearing potential who are unwilling to employ adequate contraception\n* T-cell lymphoma\n* Receiving treatment for small and chronic lymphocytic lymphoma\n* Grade 3B follicular lymphoma","ALL","18 Years",{"count":19,"type":20},112,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patients with indolent non-Hodgkin lymphoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Standard of care radiation treatment for indolent non-Hodgkin lymphoma is usually delivered in 12 treatments. Studies have shown indolent lymphoma to be sensitive to radiation treatment, however, larger doses have higher rates of toxicities. A reduced radiation dose may be safe, tolerable and\u002For effective compared to standard of care radiation dose in treating patients with indolent non-Hodgkin lymphoma.",[26,27,28,29,30],"Indolent B-Cell Non-Hodgkin Lymphoma","Recurrent Indolent B-Cell Non-Hodgkin Lymphoma","Refractory Indolent B-Cell Non-Hodgkin Lymphoma","Recurrent Indolent Non-Hodgkin Lymphoma","Refractory Indolent Non-Hodgkin Lymphoma","RECRUITING","2026-04-17",{"date":34,"type":35},"2026-04-22","ACTUAL",{"date":37,"type":35},"2024-05-15",{"date":39,"type":20},"2027-05-30",{"name":41,"class":42},"Mayo Clinic","OTHER",7,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100600505","phase-1-st-067-in-combination-with-cd19-directed-car-t-cell-therapy-liso-cel-in-relapsedrefractory-large-b-cell-lymphoma-100600505","NCT07098364","ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed\u002FRefractory Large B-Cell Lymphoma","A Phase 1\u002F2 Open-Label Study Evaluating the Safety and Efficacy of ST-067 in Combination With CD19-Directed CAR T-Cell Therapy in Patients With Relapsed\u002FRefractory (R\u002FR) Large B-Cell Lymphoma (LBCL)","Inclusion Criteria:\n\n* Male or female \\>= 18 years of age at the time of consent\n* Patients with LBCL (including diffuse large B-cell lymphoma \\[DLBCL\\] not otherwise specified \\[including DLBCL arising from indolent lymphoma\\], high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B) with at least 2 lines of systemic therapy and an Food and Drug Administration (FDA)-approved indication for treatment with liso-cel\n* Fluorodeoxyglucose (FDG)-avid disease on PET imaging before lymphodepletion or pathology evidence of active disease\n* Evidence of CD19 expression on any prior or current tumor specimen or a high likelihood of CD19 expression based on disease histology\n* Karnofsky performance status \\>= 60%\n* Adequate bone marrow function for lymphodepletion chemotherapy defined as: absolute neutrophil count (ANC) \\>= 1000 cells\u002Fmm\\^3, platelets \\>= 50,000 cells\u002Fmm\\^3, and hemoglobin \\>= 8 g\u002FdL, unless the cytopenias are due to bone marrow involvement by lymphoma in the opinion of the principal investigator (PI)\n* Calculated creatinine clearance (Cockcroft\u002FGault) \\> 30 mL\u002Fmin\u002F1.73 m\\^2\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\\\u003C 3 x upper limit of normal (ULN) (or \\\u003C 5 x ULN for subjects with lymphomatous infiltration of the liver) and total bilirubin =\\\u003C 2 (or \\\u003C 3.0 for subjects with Gilbert's syndrome, lymphomatous infiltration of the liver, or hemolysis)\n* Adequate pulmonary function based on pulmonary function testing (PFT), defined as forced expiratory volume in 1 second (FEV1) and FEV1\u002Fforced vital capacity (FVC) ratio of \\>= 60% of predicted value and diffusing capacity of the lung for carbon monoxide (DLCO; corrected) \\>= 40% of predicted value\n* Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) \\>= 40% as assessed by echocardiogram or multiple uptake gated acquisition (MUGA)\n* Women of reproductive potential (defined as all women physiologically capable of becoming pregnant) must agree to use suitable methods of contraception for at least 30 days after the last dose of study therapy (ST-067)\n* Males who have partners of reproductive potential must agree to use an effective barrier contraceptive method for at least 90 days after the last dose of study therapy (ST-067)\n* Ability to understand and provide informed consent\n* Able and willing to comply with study visit schedule and procedures, including tumor biopsy where feasible and with acceptable risk\n\nExclusion Criteria:\n\n* Planned use of out-of-specification liso-cel product\n* History of another malignancy. The following are exceptions to this criterion:\n\n  * Adequately treated basal cell or squamous cell carcinoma of the skin.\n  * In situ prostate, ductal breast carcinoma breast, and cervical carcinoma.\n  * Adequately treated papillary, noninvasive bladder cancer.\n  * Other adequately treated stage 1 or 2 cancers currently in complete remission.\n  * Any other cancer that has been in remission for \\>= 2 years\n* Planned use of therapeutic doses of corticosteroids (\\> 20 mg\u002Fday prednisone or equivalent) or other systemic immunosuppression within 7 days prior to leukapheresis or within 72 hours prior to liso-cel infusion. Topical and\u002For inhaled steroids are permitted\n* Prior treatment with any CD19 CAR T-cell therapy\n* For allogeneic hematopoietic cell transplant recipients, active graft versus host disease (GVHD) and\u002For systemic GVHD therapy within 30 days prior to planned leukapheresis\n* Known active hepatitis B (detectable hepatitis B deoxyribonucleic acid \\[DNA\\]) or hepatitis C (detectable hepatitis C ribonucleic acid \\[RNA\\])\n* Known human immunodeficiency virus (HIV) infection\n* Pregnant or breastfeeding women\n* Prior treatment with any IL-1 or IL-18 agonist and\u002For biosimilar agents, or an investigational agent within 4 weeks or 5 half-lives, whichever is shorter, prior to start of lymphodepletion\n* Active autoimmune or inflammatory disorders (including inflammatory bowel disease \\[e.g., ulcerative colitis, Crohn's disease\\], celiac disease, or other serious chronic gastrointestinal conditions associated with diarrhea, autoimmune vasculitis, systemic lupus erythematosus, Wegener syndrome \\[granulomatosis with polyangiitis\\], myasthenia gravis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.) requiring immunosuppressive therapy. The following are exceptions to this criterion:\n\n  * Vitiligo.\n  * Alopecia.\n  * Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement.\n  * Type 1 diabetes mellitus.\n  * Psoriasis not requiring systemic treatment.\n  * Conditions considered to be low risk of serious deterioration by the PI\n* History of any one of the following cardiovascular conditions within the past 6 months, unless clearance by a cardiologist is obtained: class III or IV heart failure as defined by the New York Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, or unstable angina. History of other clinically significant cardiac disease that, in the opinion of the PI or designee, is a contraindication to study treatment is also excluded\n* Significant electrocardiogram (ECG) abnormalities, including unstable cardiac arrhythmia requiring medication, second-degree atrioventricular (AV) block type II, third-degree AV block, \\>= grade 2 bradycardia, or QT interval corrected using Fridericia's formula \\> 500 ms irrespective of gender\n* History or presence of clinically relevant central nervous system (CNS) pathology, such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, or psychosis that in the opinion of the PI is a contraindication to study treatment.\n\n  * Patients with active parenchymal CNS involvement by malignancy will be excluded. Patients with prior or current secondary leptomeningeal CNS disease are eligible. CNS disease prophylaxis must be stopped at least 1 week prior to liso-cel infusion\n* History of solid organ transplantation\n* Active, serious, and uncontrolled infection(s)",{"count":52,"type":20},33,[54,23],"PHASE1","This phase I\u002FII trial tests the safety, side effects, and best dose\u002Fregimen of ST-067 in combination with CD19-directed chimeric antigen receptor (CAR) T-cell therapy (liso-cel) and how well it works in treating patients with large B-cell lymphoma (LBCL) that has come back after a period of improvement (recurrent) or LBCL that has not responded to previous treatment (refractory). ST-067 is an engineered variant of the human cytokine interleukin-18 that may help the immune system kill cancer cells. Lisocabtagene maraleucel (liso-cel) is an autologous CAR T-cell therapy prepared using the person's own immune system (a group of cells, tissues, and organs that protect the body from attack by bacteria, viruses, and cancer cells) to fight the cancer. Giving ST-067 in combination with liso-cel may better treat patients with relapsed\u002Frefractory LBCL.",[57,58,59,60,27,61,62,63,64,65,28,66],"Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Recurrent Grade 3b Follicular Lymphoma","Recurrent High-Grade B-Cell Lymphoma","Recurrent Primary Mediastinal Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Refractory Grade 3b Follicular Lymphoma","Refractory High-Grade B-Cell Lymphoma","Refractory Primary Mediastinal Large B-Cell Lymphoma","2026-01-13",{"date":69,"type":35},"2026-01-14",{"date":71,"type":35},"2025-12-27",{"date":73,"type":20},"2043-10-04",{"name":75,"class":42},"Fred Hutchinson Cancer Center",1]